Answers are grounded in this paper and cite their sources.
Objective To investigate the dynamic progression and key turning points of quality-of-life (QoL) impairment in patients with capecitabine-induced hand-foot syndrome (HFS) and identify the optimal timing for rehabilitation intervention. Methods This secondary analysis included 234 breast cancer patients receiving capecitabine from a multicenter, double-blind randomized controlled trial. HFS-related QoL (HF-QoL), EORTC QLQ-C30, and QLQ-BR23 were assessed longitudinally. Generalized estimating equations examined HFS grade-by-time interactions, and clinically significant deterioration was defined using the minimum clinically important difference (MCID ≥10 points). Results Significant HFS grade-by-time interactions were observed for HF-QoL (β=1.215, 95% CI = [0.689, 1.741], P < 0.001), QLQ-C30 (β=1.464, 95% CI = [0.820, 2.109], P < 0.001), and QLQ-BR23 (β=0.451, 95% CI = [0.148,0.753], P = 0.004), indicating accelerated QoL deterioration with increasing HFS severity. The proportion of patients with clinically significant HF-QoL deterioration increased sharply from Grade 1 to Grade 2 (18.9% vs. 41.9%; OR = 3.053, P = 0.010). Conclusion HFS severity and QoL deterioration show divergent trajectories; Grade 2 may represent a critical threshold at which QoL impairment crosses the threshold of clinical significance; progression from HFS Grade 1 to Grade 2 may be a potential time point for validation in future prospective rehabilitation intervention studies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: